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Abstract
Background Human papilloma virus (HPV) prevalence
studies performed in different regions and population
groups across Canada would inform public health decisions
regarding implementation of anti-HPV vaccines.
Methods A total of 8,700 liquid-based specimens
from 8,660 women aged 13–86 from throughout British
Columbia were collected. DNA was isolated from 4,980 of
these samples and assessed for HPV prevalence and type
distribution. HPV was detected by PCR analysis using
tagged GP5?/6? consensus primers to amplify the L1
region of HPV; typing was done by bi-directional
sequencing of PCR products.
Results Overall HPV prevalence was 16.8% (age adjus-
ted 15.5%). Prevalence of high-risk HPV was 13.9, and
10.7% of samples contained HPV16. HPV prevalence was
highest in the youngest group of women (\20 years). One-
third of HPV positive samples contained more than one
HPV type. Percentages of low-grade (LGIL) and high-
grade intraepithelial lesions (HGIL) containing high-risk
HPV are 52.3 and 79.4%, respectively.
Conclusions Overall HPV prevalence in this study is
within the range of estimates from other studies. The
prevalence of HPV16 is higher than what is found in other
Canadian and international studies. HPV16 and HPV18
compose a majority of the high-risk virus in this study. Use
of current HPV vaccines could considerably reduce HPV-
related conditions including cervical cancer and procedures
such as colposcopy.
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Introduction
Human papillomavirus (HPV) is now understood to be
necessary but insufﬁcient for the development of cervical
cancer [1]. There are more than 100 known types of HPV,
of which over 40 infect the female genital tract. Of these, at
least 15 are denoted as ‘high risk’ (HR) [2] for cervical
cancer.
The recent development of vaccines against two (HPV
types 16 and 18) [3, 4] or four (HPV types 16, 18, 6, and
11) [5–7] HPV types has highlighted the need for timely
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data can be used to estimate the expected effectiveness of
these vaccines in reducing conditions and procedures
arising from those HPV types. It can also establish a
baseline from which to monitor potential changes in HPV
prevalence and type distribution after uptake of a vaccine.
Our objective was to establish baseline HPV prevalence
and HPV type distribution in women who participated in
the population-based cervical cytology screening program
in British Columbia in 2004, to enable optimal public
health decision-making regarding prevention of cervical
cancer and related conditions.
Methods
Study population
The centralized cervical cancer screening program (CCSP)
of BC has been operational since 1960. It processes every
Pap smear done in BC at a single facility; all cytology
results are stored in a single database. More than half a
million women participate in the CCSP each year and over
70% of eligible women in BC are screened, on average,
every 30 months.
Specimen collection and cytological interpretation
A ﬂowchart summarizing sample collection and experi-
ments is shown in Supplemental Online Figure A. The
8,700 samples used in this study were derived from a
feasibility study of liquid-based smears collected by 99
high-volume smear-takers from different parts of BC
within the CCSP between March and July 2004 [8]. The
sample included women aged 13–86; median age was 38.
About 98.2% of the smears in this study are from the cervix
or endocervix; 1.8% from vaginal samples. Practitioners
were instructed to obtain the sample from the transforma-
tion zone of the cervix using a Rovers Cervex Brush.
Swabs were placed in SurePath
 media. TriPath Imaging
Inc. equipment was used to process samples according to
the manufacturer’s instructions. Cervical smears were
interpreted by Canadian-registered CCSP cytotechnologists
and the BC Cancer Agency-based cytopathologists. Cyto-
logical interpretation was reported using the British Society
of Clinical Cytology terminology currently in use in BC.
For this analysis, however, results were reclassiﬁed using
the Bethesda system. Negative and benign changes were
kept as originally categorized. Mild dyskariosis was clas-
siﬁed as low-grade intraepithelial lesions (LGIL) of the
squamous or glandular type; moderate or severe dyskari-
osis and suspicious smears were classiﬁed as high-grade
intraepithelial lesions (HGIL) of the squamous or glandular
type. Smears showing squamous (87.7%) and glandular
(12.3%) abnormalities were not separated in our main
analysis of LGIL or HGIL for simplicity of data presen-
tation. Individual typing data has been separated by glan-
dular or squamous type and is included in a separate table
(Table 1). The categories of ASCUS and AGUS were not
used.
This study was approved by the joint Clinical Research
Ethics Board of the BC Cancer Agency and the University
of British Columbia. Use of specimens for this study was
performed according to the ‘Secondary Use of Personal
Information in Health Research: Case Studies’ (Canadian
Institutes of Health Research, November 2002). Cytology
results were recorded in the CCSP database. Each sample
was assigned a study number, and the data including the
age of the participant, geographic region of the smear taker,
cytology result and previous screening history were
attached to the study number. Subsequently, the remainder
of each sample and the data were stripped of potential
patient identiﬁers. The data and samples left over after
cytology were then transferred to the Genome Sciences
Centre at the BC Cancer Research Centre for HPV
analysis.
Study sample selection
From the total study sample set of 8,700, forty samples
were from repeat smears from the same women and were
excluded, leaving 8,660 independent samples. PCR anal-
ysis was performed on 4,980 samples including all 614
cytologically abnormal samples and a random selection
(every second sample by study number) of 4,366 normal
and benign cytology smears. This sample showed a rep-
resentative distribution to that of the remaining samples.
Neither normal nor benign smears showed a statistically
signiﬁcant difference in age distribution or geographic
location between selected and not selected smears. Age
was tested using the t-test, and also using Mantel-Hanzel
chi-square analysis with six age categories (\20, 20–29,
30–39, 40–49, 50–59 and 60?). Geographic location was
tested using the chi-square test.
DNA extraction, quantiﬁcation and quality control
The portion of each sample remaining after cytology (1–
6 ml) was pelleted by centrifugation, re-suspended in
300 ll of phosphate-buffered saline, and stored at -80C.
DNA was extracted from 150 ll of thawed re-suspended
cellular material using the PureGene DNA isolation kit
(Gentra Systems, MN, USA). DNA samples were quanti-
ﬁed by ﬂuorometry and 10 ng aliquots arrayed in 96-well
plates for PCR analysis. Plates were arrayed according
to sample number and were not separated according to
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123cytology. The b-globin gene primers were used to conﬁrm
the competence each DNA sample to support PCR. The
percentage of samples that passed this quality control test is
96.8% (4,821 samples) samples that did not pass this test
were not included in HPV testing (see Supplemental
Online Figure A).
Table 1 HPV type distribution
according to cellular origin of
abnormality, 95% CI shown in
brackets
Cell type could not be
determined for three patients.
Their results are not shown in
the table
a HPV of unidentiﬁed type
LGIL squamous (%) LGIL adeno. (%) HGIL squamous (%) HGIL adeno (%)
Sample no. 441 61 52 9
HPV? 70.3 (65.8, 74.5) 62.3 (48.9, 74.1) 80.8 (67.0, 89.9) 77.8 (40.2, 96.1)
Any HR type 53.1 (48.3, 57.8) 45.9 (33.3, 59.1) 78.8 (64.9, 88.5) 77.8 (40.2, 96.1)
16 or 18 36.5 (32.0, 41.2) 45.9 (33.3, 59.1) 61.5 (47.0, 74.4) 66.7 (30.9, 91.0)
16 33.8 (29.4, 38.4) 44.3 (31.8, 57.5) 51.9 (37.8, 65.8) 55.6 (22.7, 84.7)
18 5.4 (3.6, 8.1) 9.8 (4.1, 20.9) 23.1 (13.0, 37.2) 11.1 (0.6, 49.3)
26 0.0 (0.0, 1.1) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
31 2.7 (1.5, 4.8) 0.0 (0.0, 7.4) 3.8 (0.7, 14.3) 0.0 (0.0, 37.1)
33 5.2 (3.4, 7.8) 4.9 (1.3, 14.6) 7.7 (2.5, 19.4) 0.0 (0.0, 37.1)
35 5.2 (3.4, 7.8) 6.6 (2.1, 16.7) 3.8 (0.7, 14.3) 0.0 (0.0, 37.1)
39 0.2 (0.0, 1.5) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
45 1.4 (0.6, 3.1) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
51 0.0 (0.0, 1.1) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
52 0.2 (0.0, 1.5) 1.6 (0.1, 10.0) 3.8 (0.7, 14.3) 0.0 (0.0, 37.1)
53 0.0 (0.0, 1.1) 1.6 (0.1, 10.0) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
56 7.0 (4.9, 9.9) 6.6 (2.1, 16.7) 1.9 (0.1, 11.6) 0.0 (0.0, 37.1)
58 2.3 (1.2, 4.3) 1.6 (0.1, 10.0) 7.7 (2.5, 19.4) 0.0 (0.0, 37.1)
59 0.7 (0.2, 2.1) 1.6 (0.1, 10.0) 3.8 (0.7, 14.3) 0.0 (0.0, 37.1)
66 2.5 (1.3, 4.6) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 11.1 (0.6, 49.3)
68 0.2 (0.0, 1.5) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
73 0.7 (0.2, 2.1) 0.0 (0.0, 7.4) 1.9 (0.1, 11.6) 0.0 (0.0, 37.1)
82 0.2 (0.0, 1.5) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
Any LR type 25.2 (21.2, 29.5) 23.0 (13.5, 35.8) 5.8 (1.5, 16.9) 11.1 (0.6, 49.3)
6 or 11 15.2 (12.0, 19.0) 18.0 (9.8, 30.4) 3.8 (0.7, 14.3) 11.1 (0.6, 49.3)
6 14.7 (11.6, 18.5) 14.8 (7.4, 26.7) 3.8 (0.7, 14.3) 11.1 (0.6, 49.3)
11 0.9 (0.3, 2.5) 4.9 (1.3, 14.6) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
30 0.7 (0.2, 2.1) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
42 1.6 (0.7, 3.4) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
43 0.2 (0.0, 1.5) 0.0 (0.0, 7.4) 1.9 (0.1, 11.6) 0.0 (0.0, 37.1)
44 0.0 (0.0, 1.1) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
54 1.1 (0.4, 2.8) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
61 0.0 (0.0, 1.1) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
63 0.0 (0.0, 1.1) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
67 1.8 (0.8, 3.7) 1.6 (0.1, 10.0) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
69 0.0 (0.0, 1.1) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
70 0.5 (0.1, 1.8) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
72 0.7 (0.2, 2.1) 4.9 (1.3, 14.6) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
74 0.2 (0.0, 1.5) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
81 0.9 (0.3, 2.5) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
83 0.0 (0.0, 1.1) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
84 0.2 (0.0, 1.5) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
87 0.5 (0.1, 1.8) 0.0 (0.0, 7.4) 1.9 (0.1, 11.6) 0.0 (0.0, 37.1)
89 0.0 (0.0, 1.1) 0.0 (0.0, 7.4) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
90 3.6 (2.2, 5.9) 3.3 (0.6, 12.4) 1.9 (0.1, 11.6) 0.0 (0.0, 37.1)
HPV X
a 1.4 (0.6, 3.1) 4.9 (1.3, 14.6) 0.0 (0.0, 8.6) 0.0 (0.0, 37.1)
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Tagged GP5?/GP6? consensus primers [9, 10] were used
to detect HPV by amplifying a 150 bp sequence of the viral
L1 gene from virtually any HPV type, and bi-directional
sequencing was used to determine HPV type(s) present in
each sample. The GP5?/6? primers [9, 10] were modiﬁed
by the addition of SeqA2 (GAATTCTCTAGATGATCA
GCGGC) or Seq B2 (CGAACTTTATTCGGTCGAAAA
GG) tags to their 50 ends to simplify later sequencing.
Testing of known HPV types mixed with genomic DNA
demonstrated effectiveness of the tagged primers in
detecting various HPV types. PCR analysis was carried out
as previously described [9] with minimal changes (95C
30 s, 40C 1 min, 68C 30 s for 40 cycles). An aliquot of
each PCR product was separated on a 3% agarose gel for
visualization. Samples that showed the expected 150 bp
band were designated as HPV positive. Aliquots of PCR
products from HPV positive samples were then re-arrayed
into 96-well plates and puriﬁed by the AMPure magnetic
bead system (Agencourt Bioscience Corporation, Beverly,
Massachusetts, USA). Puriﬁed PCR products were bi-
directionally sequenced using BigDye 3.1 at 1/24 chemis-
try and run on 3730xl capillary sequencers (Applied Bio-
systems, Foster City, California). Sequence traces that
produced apparent multiple overlapping sequences were
ﬂagged as possible multiple infections (MI). PCR products
from such samples were phosphorylated with polynucleo-
tide kinase (New England BioLabs, MA, USA) and sub-
cloned by blunt end ligation into pUC19. Sixteen clones of
each putative MI were bi-directionally sequenced using the
-21 M13 Forward (TGTAAAACGACGGCCAGT) and
M13 Reverse (CAGGAAACAGCTATGAC) primers.
Sequences were aligned to a database of all known HPV L1
sequences using local BLAST alignment, and the best
match scored as a speciﬁc HPV type if it had greater than
95% similarity over more than 50 bases.
For this study types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 68, 73, and 82 were considered high-risk
HPV types.
Statistical analyses
Statistical analyses were performed using the SAS package
(SAS Institute Inc., Cary, NC, USA). All cytologically
abnormal samples were HPV typed, but not all normal or
benign samples were typed; it was, therefore, necessary to
weight by cytology in the ﬁnal prevalence analyses.
Weighting was performed as follows. Column ‘‘Study
Sample’’ in Tables 2 and 3 adjusts prevalence estimated
from successful HPV testing to reﬂect cytology distribution
in the study sample. The weight for each normal, benign,
LGIL and HGIL is the proportion it constitutes of the study
sample, divided by the proportion it constitutes of suc-
cessful HPV tests. Multiply infected samples were deﬁned
as samples for which two or more HPV types were
detected. Such samples were counted as a positive for one
type of HPV and also included among positives for another
or other types of HPV, in calculations of the prevalence of
each HPV type.
The Cochrane–Armitage trend test was used on HPV
prevalenceratesby5-yearagegroupsshowninFigs. 1and2a.
Results
Study participants are representative of the CCSP in
terms of age, cytology and geographical distribution
Table 4 shows the age distribution of the study sample set
compared to that of the entire CCSP in 2004, including
95% CI. While the difference in some categories is sta-
tistically signiﬁcant, differences are small in practical
terms. Furthermore, adjustment by age, by cytology or both
has been included among HPV prevalence estimates. The
age distribution is comparable, except that the study sam-
ple shows modest over-recruitment of women in the two
youngest (\20 and 20–24 year old) age groups. The dis-
tribution of cytology is similar to that of the CCSP
(Table 4). Of the 8,660 independent samples, 9 were
unsatisfactory for interpretation. Of the interpretable sam-
ples, 65 showed high-grade intraepithelial lesions (HGIL,
0.8%), 549 showed low-grade intraepithelial lesions
(LGIL, 6.3%), 413 showed benign changes (4.8%), and the
remaining 7,624 were cytologically normal (88.1%) [8].
Table 4 also shows that the study sample is distributed, by
health authority region, comparably to the CCSP.
Prevalence and type distribution
Table 2 summarizes both the overall HPV prevalence and
type distribution by cytology, with 95% conﬁdence inter-
vals. Figure 1 illustrates these data graphically. The overall
HPV prevalence of the study population, adjusted from the
data for the 4,980 tested samples as described earlier, was
16.8%. Of them 13.9% were positive for high risk HPV,
and 11.6% had the high risk types 16 or 18 that are targeted
by vaccines. HPV prevalence increases with each more-
severe cytological category. HPV16 is the most common
type, found in 10.7% of samples. The HPV16 prevalence
generally increases with the severity of the abnormalities
that are precursors to cervical cancer; it is present in 8.7%
of cytologically normal samples, 35.2% of LGIL and
52.4% of HGIL. Age-adjusted data can be found in Sup-
plemental Online Table A. Adjusting for age slightly
reduces the prevalence of HPV overall (to 15.5%) and in
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123Table 2 HPV Prevalence and type distribution, shown by cytology group, (95% CI shown in parentheses)
Study sample
a Normal Benign LGIL HGIL
Sample no. 4,821 4,003 250 505 63
HPV? 16.8 (15.8, 17.9) 12.3 (11.3, 13.4) 19.6 (15.0, 25.2) 69.3 (65.0, 73.3) 81.0 (68.7, 89.4)
Any HR type 13.9 (13.0, 14.9) 10.6 (9.6, 11.6) 14.4 (10.4, 19.5) 52.3 (47.8, 56.7) 79.4 (67.0, 88.1)
16 or 18 11.6 (10.8, 12.6) 9.3 (8.5, 10.3) 10.8 (7.4, 15.5) 37.8 (33.6, 42.2) 63.5 (50.4, 75.0)
16 10.7 (9.8, 11.6) 8.7 (7.9, 9.6) 7.6 (4.8, 11.8) 35.2 (31.1, 39.6) 52.4 (39.5, 65.0)
18 3.5 (3.1, 4.1) 3.1 (2.6, 3.7) 5.6 (3.2, 9.4) 5.9 (4.1, 8.5) 22.2 (13.1, 34.8)
26 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 1.9) 0.0 (0.0, 0.9) 0.0 (0.0, 7.2)
31 0.4 (0.3, 0.7) 0.2 (0.1, 0.4) 0.8 (0.1, 3.2) 2.4 (1.3, 4.2) 3.2 (0.6, 12.0)
33 1.1 (0.9, 1.5) 0.8 (0.6, 1.2) 0.4 (0.0, 2.6) 5.1 (3.5, 7.6) 6.3 (2.1, 16.3)
35 0.9 (0.6, 1.2) 0.5 (0.3, 0.8) 0.4 (0.0, 2.6) 5.3 (3.6, 7.8) 3.2 (0.6, 12.0)
39 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 1.9) 0.2 (0.0, 1.3) 0.0 (0.0, 7.2)
45 0.6 (0.4, 0.9) 0.6 (0.4, 0.9) 0.0 (0.0, 1.9) 1.2 (0.5, 2.7) 0.0 (0.0, 7.2)
51 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 1.9) 0.0 (0.0, 0.9) 0.0 (0.0, 7.2)
52 0.1 (0.0, 0.2) 0.0 (0.0, 0.2) 0.0 (0.0, 1.9) 0.4 (0.1, 1.6) 3.2 (0.6, 12.0)
53 0.1 (0.0, 0.2) 0.0 (0.0, 0.2) 0.4 (0.0, 2.6) 0.2 (0.0, 1.3) 0.0 (0.0, 7.2)
56 2.0 (1.6, 2.4) 1.6 (1.3, 2.1) 2.0 (0.7, 4.9) 6.9 (4.9, 9.6) 1.6 (0.1, 9.7)
58 0.7 (0.5, 1.0) 0.6 (0.4, 0.9) 0.0 (0.0, 1.9) 2.2 (1.1, 4.0) 6.3 (2.1, 16.3)
59 0.5 (0.3, 0.7) 0.4 (0.2, 0.7) 0.8 (0.1, 3.2) 0.8 (0.3, 2.2) 3.2 (0.6, 12.0)
66 0.9 (0.7, 1.2) 0.8 (0.6, 1.1) 1.2 (0.3, 3.8) 2.2 (1.1, 4.0) 1.6 (0.1, 9.7)
68 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 1.9) 0.2 (0.0, 1.3) 0.0 (0.0, 7.2)
73 0.2 (0.1, 0.4) 0.1 (0.0, 0.3) 0.4 (0.0, 2.6) 0.6 (0.2, 1.9) 1.6 (0.1, 9.7)
82 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 1.9) 0.2 (0.0, 1.3) 0.0 (0.0, 7.2)
Any LR type 7.0 (6.3, 7.7) 5.6 (4.9, 6.3) 8.8 (5.7, 13.2) 25.0 (21.3, 29.0) 6.3 (2.1, 16.3)
6 or 11 4.2 (3.7, 4.8) 3.3 (2.8, 3.9) 5.6 (3.2, 9.4) 15.6 (12.6, 19.2) 4.8 (1.2, 14.2)
6 4.0 (3.5, 4.6) 3.2 (2.7, 3.8) 5.2 (2.9, 8.9) 14.9 (11.9, 18.3) 4.8 (1.2, 14.2)
11 0.2 (0.1, 0.4) 0.1 (0.0, 0.3) 0.4 (0.0, 2.6) 1.4 (0.6, 3.0) 0.0 (0.0, 7.2)
30 0.2 (0.1, 0.3) 0.1 (0.0, 0.3) 0.4 (0.0, 2.6) 0.6 (0.2, 1.9) 0.0 (0.0, 7.2)
42 0.2 (0.1, 0.4) 0.1 (0.1, 0.3) 0.0 (0.0, 1.9) 1.4 (0.6, 3.0) 0.0 (0.0, 7.2)
43 0.3 (0.2, 0.5) 0.3 (0.2, 0.6) 0.0 (0.0, 1.9) 0.2 (0.0, 1.3) 1.6 (0.1, 9.7)
44 0.0 (0.0, 0.1) 0.0 (0.0, 0.2) 0.0 (0.0, 1.9) 0.0 (0.0, 0.9) 0.0 (0.0, 7.2)
54 0.5 (0.3, 0.8) 0.5 (0.3, 0.8) 0.4 (0.0, 2.6) 1.0 (0.4, 2.4) 0.0 (0.0, 7.2)
61 0.0 (0.0, 0.2) 0.0 (0.0, 0.2) 0.4 (0.0, 2.6) 0.0 (0.0, 0.9) 0.0 (0.0, 7.2)
63 0.0 (0.0, 0.1) 0.0 (0.0, 0.2) 0.0 (0.0, 1.9) 0.0 (0.0, 0.9) 0.0 (0.0, 7.2)
67 0.6 (0.4, 0.9) 0.6 (0.4, 0.9) 0.4 (0.0, 2.6) 1.8 (0.9, 3.5) 0.0 (0.0, 7.2)
69 0.0 (0.0, 0.1) 0.0 (0.0, 0.2) 0.0 (0.0, 1.9) 0.0 (0.0, 0.9) 0.0 (0.0, 7.2)
70 0.2 (0.1, 0.4) 0.2 (0.1, 0.4) 0.0 (0.0, 1.9) 0.4 (0.1, 1.6) 0.0 (0.0, 7.2)
72 0.2 (0.1, 0.4) 0.1 (0.0, 0.3) 0.0 (0.0, 1.9) 1.2 (0.5, 2.7) 0.0 (0.0, 7.2)
74 0.1 (0.0, 0.2) 0.1 (0.0, 0.2) 0.0 (0.0, 1.9) 0.2 (0.0, 1.3) 0.0 (0.0, 7.2)
81 0.3 (0.2, 0.5) 0.2 (0.1, 0.4) 0.8 (0.1, 3.2) 0.8 (0.3, 2.2) 0.0 (0.0, 7.2)
83 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.4 (0.0, 2.6) 0.0 (0.0, 0.9) 0.0 (0.0, 7.2)
84 0.1 (0.0, 0.2) 0.1 (0.0, 0.2) 0.0 (0.0, 1.9) 0.2 (0.0, 1.3) 0.0 (0.0, 7.2)
87 0.1 (0.1, 0.3) 0.1 (0.0, 0.3) 0.0 (0.0, 1.9) 0.4 (0.1, 1.6) 1.6 (0.1, 9.7)
89 0.0 (0.0, 0.1) 0.0 (0.0, 0.2) 0.0 (0.0, 1.9) 0.0 (0.0, 0.9) 0.0 (0.0, 7.2)
90 1.4 (1.1, 1.8) 1.2 (0.9, 1.6) 2.4 (1.0, 5.4) 3.6 (2.2, 5.7) 1.6 (0.1, 9.7)
HPV X
b 0.2 (0.1, 0.3) 0.0 (0.0, 0.2) 0.4 (0.0, 2.6) 1.8 (0.9, 3.5) 0.0 (0.0, 7.2)
a Weighting in this column is by cytology
b HPV of unidentiﬁed type
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123normal cytology (to 12.1%), as well as the overall preva-
lence of HPV16 (to 10.2%).
Figure 1 illustrates a striking difference between HR
and LR HPV types. HR types (16, 18 or all HR types as a
group) show higher prevalence in samples with HGIL than
in those with LGIL, whereas the reverse is true for LR
types (6, 11, all LR types together). This is consistent with
the ﬁndings that LR types are less likely to be associated
with progression to cervical cancer.
Figure 2a, b shows HPV prevalence and type distribu-
tion by age. Overall HPV positivity, and both high risk and
low risk types are most prevalent in women under age 20,
with decreasing prevalence seen up to approximately age
60. Trend was highly signiﬁcant for any HPV type, any
high risk type, and low risk type, at p\0.0001 for each,
signiﬁcant for HPV 16/18 at p = 0.0004 and HPV 16 at
p = 0.0153, and not signiﬁcant for HPV 18 at p = 0.2217.
Table 3 shows the rates of multiple infections (MI)
involving different combinations of HPV types, by cytol-
ogy; Supplemental Online Table B lists age-adjusted MI
rates. While the percentage of samples that have MI
increases with the severity of the cytological abnormality,
dividing the MI rate by the percentage of HPV positives in
each category illustrates that the percentage of HPV posi-
tive samples that have MI decreases with increasing
severity of the lesions (from 39.8% in normal samples to
19.8% in LGIL and 17.2% in HGIL). HGIL have a higher
percentage of MI only because they have more HPV; the
HPV infections they have are more likely to be single HPV
types.
Discussion
This study provides an estimate of the prevalence of HPV
in women participating in routine cytology screening in
BC. This is the largest typing study of its kind in Canada to
date and one of the largest single-center studies worldwide.
While the HPV prevalence of screened women is not
necessarily equivalent to that of all women [11] in BC, the
high participation rate of the CCSP (70% [12]) argues that
it provides a good estimate for the province. The use of
direct sequencing theoretically allows the detection of all
known HPV types and provides a level of detail not
attainable using existing hybridization probe sets or the
Digene Hybrid Capture 2 system.
Several international studies have examined the preva-
lence of HPV in women. The diversity of population
samples, sample media and HPV typing methods make it
difﬁcult to identify studies that are exactly comparable to
Table 3 Multiple infections, shown by cytology group (95% CI shown in parentheses)
Study Sample
a Normal Benign LGIL HGIL
Sample no. 4,821 4,003 250 505 63
HPV? 16.8 (15.8, 17.9) 12.3 (11.3, 13.4) 19.6 (15.0, 25.2) 69.3 (65.0, 73.3) 81.0 (68.7, 89.4)
MI rate 5.5 (4.9, 6.2) 4.9 (4.3, 5.6) 4.3 (2.2, 8.1) 13.7 (10.2, 18.2) 13.9 (5.2, 30.3)
MI any HR 5.4 (4.8, 6.1) 4.8 (4.2, 5.5) 4.3 (2.2, 8.1) 13.4 (9.9, 17.9) 13.9 (5.2, 30.3)
MI any LR 4.3 (3.7, 4.9) 3.9 (3.4, 4.5) 3.9 (1.9, 7.5) 10.1 (7.1, 14.2) 5.6 (1.0, 20.0)
MI any HR with any LR 4.3 (3.7, 4.9) 3.9 (3.3, 4.5) 3.9 (1.9, 7.5) 9.8 (6.8, 13.8) 5.6 (1.0, 20.0)
16 MI 4.7 (4.1, 5.3) 4.3 (3.7, 5.0) 3.0 (1.3, 6.4) 10.5 (7.4, 14.6) 11.1 (3.6, 27.0)
18 MI 2.9 (2.5, 3.5) 2.7 (2.3, 3.3) 3.5 (1.6, 7.0) 4.2 (2.4, 7.3) 13.9 (5.2, 30.3)
6 MI 3.3 (2.8, 3.8) 2.9 (2.4, 3.5) 3.5 (1.6, 7.0) 8.2 (5.5, 12.0) 5.6 (1.0, 20.0)
a Values in this column are weighted by cytology
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123each other. It is not surprising that our HPV type distri-
bution differs from that of a large US study based on self-
sampled vaginal swabs [13]. Low-risk HPV types that are
more prevalent in the vagina and vulva [14] will not be
well represented in our samples, as these are almost
exclusively cervical smears. It is also reported that self-
collected vaginal sampling methods are generally less
sensitive than cervical smears for the detection of HPV [15,
16]. Overall HPV infection rates in population-based
studies where all women were included found HPV prev-
alence rates from 2% in Hanoi, Vietnam [17], to 40% in
Mozambique [18]. Our overall HPV infection rate was
16.8%, close to that of an Ontario study (13.3%) [19]. A
recent large study in The Netherlands typing high-risk HPV
in the population found a rate of 5.6% [20] and shows a
similar trend for age as observed in our study (Fig. 2a, b).
Our prevalence is also at a similar level to that seen in a
recent, large meta-analysis for Asian women at 14.4% for
cytologically normal samples [21]. Prevalence of HR HPV
ranged from 4.4% [22] to almost 20% [23] in these studies,
in keeping with our rate of 13.9%. Similarly to many other
studies, HPV16 was the most common high-risk type in
BC. We found a higher prevalence of HPV16 (10.7%) than
other studies, which showed less than 1% to just over 5%.
Several studies [17, 22–28] used GP5?/6? primers,
but detected HPV types by hybridization followed by
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123enzyme-based immunoassay. Our method subjects the PCR
products to an additional, albeit linear, ampliﬁcation in the
sequencing reaction, likely enhancing the sensitivity of
detection. Comparison of cycle sequencing, line blotting
and hybrid capture showed that sequencing is the most
sensitive [29].
HPV positivity increases, as expected, from normal
(12.3%), to benign (19.6%), to LGIL (69.3%), to HGIL
(81.0%). The trend for HPV 16 also makes sense, going
from normal (8.7%), benign (7.6%), LGIL (35.2%) and
HGIL (52.4%). The relative proportion of HPV16 (HPV16/
totalHPV), however, is unexpectedly high in normal sam-
ples (71%), when compared to benign (39%), LGIL (51%)
and HGIL (65%). It is unlikely that contamination could
account for this difference, because all samples were pro-
cessed on multi-well plates and were not separated
according to cytology. We propose that there is a real
biological explanation for this observation that likely
relates to the sensitivity of PCR and sequencing to detect
HPV. We may be detecting transient, sub-clinical HPV
exposures in addition to overt HPV16 infections that would
be detected with less sensitive techniques.
We found that 33% of HPV positive samples contained
multiple HPV types, within the range of 12–62% seen in
other studies [28, 30]. Direct sequencing may underesti-
mate the MI rate; however, our conservative over selection
of potential MIs (all sequence traces with any sign of
mixed types were subcloned) should compensate for this.
Our higher observed prevalence of HPV16 is not likely to
be a result of our intensive characterization of MI samples.
The percentage of HPV positive samples that had mul-
tiple infections was higher in the cytologically normal HPV
positive samples, possibly reﬂecting clonal outgrowth of
cells infected with a single HPV type in the pre-cancerous
lesions. This may imply that multiple types of HPV
simultaneously infect the same woman but not necessarily
the same individual cells, or it may reﬂect the preferential
persistence of one HPV type. Multiple infections may be
more recent infections that have had less time for one or
some of the types involved to be cleared.
We did not exclude women who were tested as a follow-
up to a previous abnormal smear. The smear-takers were
high-volume sites; this could bias toward young sexually
active women who are seeking birth control. Compared to
the CCSP in 2004, our sample has a higher proportion of
young women, who would be more likely to have current
HPV infections. Sellors and colleagues showed a lower rate
(9.6% for high-risk HPV) in older women than in younger
women [31]; we also observe this trend. Thus, our study
could slightly over estimate the prevalence of HPV infec-
tion relative to the general female population of BC.
Differences between recruitment methods can compli-
cate direct comparison of our ﬁndings to those of other
Canadian studies [11, 19, 32, 33]. An Ontario study [19]
using Digene Hybrid Capture 2 and PCR showed a prev-
alence range of 25–6% depending on age; Montreal Uni-
versity students had an HPV rate of 29% [33], similar to the
prevalence we observed in this age group. A recent inter-
national analysis by IARC [28] illustrates the differences in
type distribution in different countries. We detect HPV90,
but this type was not included in the probe set used by
IARC [28]. Types seen more commonly in Asian countries
(such as 51, 52 and 58) were not signiﬁcantly increased in
BC, despite its large Asian population. Comparison to
worldwide data [28] demonstrates our ability to detect most
or all known HPV types, despite the tendency of GP5?/6?
primer set to underestimate HPV 52 [34].
Prophylactic vaccines are nowavailable againstHR HPV
types 16 and 18. Efﬁcacy evaluations to date for these vac-
cines show 100% protection against development of LGIL
and HGIL associated with the HPV types targeted. A
Table 4 Comparison of study sample composition to the Cervical
Cancer screening program in BC, data for 2004
Study sample
(% and 95% CI)
CCSP
2004 (%)
Cytology
Normal 88.1 (87.4, 88.8) 89.9
Benign 4.8 (4.3, 5.2) 3.1
LGIL 6.3 (5.8, 6.9) 5.9
HGIL 0.8 (0.6, 0.9) 1.1
Region of BC
Vancouver coastal 60.3 (59.3, 61.4) 60.2
Fraser 18.5 (17.7, 19.3) 20.6
Interior 9.4 (8.7, 10.0) 7.5
Northern 7.5 (7.0, 8.1) 7.0
Vancouver Island 4.3 (3.8, 4.7) 4.3
Age
\20 5.4 (4.9, 5.9) 4.7
20–24 11.2 (10.5, 11.9) 9.5
25–29 10.5 (9.8, 11.1) 11.0
30–34 12.2 (11.5, 12.9) 12.8
35–39 12.0 (11.3, 12.7) 12.8
40–44 12.6 (11.9, 13.3) 13.3
45–49 12.5 (11.8, 13.2) 11.8
50–54 10.2 (9.6, 10.9) 9.2
55–59 6.5 (6.0, 7.0) 6.5
60–64 3.5 (3.1, 3.8) 4.2
65–69 2.3 (2.0, 2.6) 2.8
70? 1.1 (0.8, 1.3) 1.5
Table 4 details a comparison of the study sample to the 2004 CCSP.
Distribution by cytology, health region in BC (location where smear
was taken), and age by 5 year strata. 95% conﬁdence intervals are
shown in brackets
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123minimum estimate of the impact of a vaccine protecting
against HPV16 and HPV18 would be the proportion of a
lesion for which representative samples are positive for 16,
18, or 16 and 18, butnot other HR types of HPV. In our data,
the proportion of LGIL and HGIL samples that meet this
criterion is 29.9% for LGIL and 55.6% for HGIL (data not
shown). Conservatively, we predict that vaccinating against
HPV16 and 18 would, in an effectively vaccinated group,
preventthedevelopmentofone-thirdofLGILandmorethan
half of HGIL, and an even larger proportion of cervical
cancer. If these estimates are expressed as a percentage of
those LGIL and HGIL that had detectable HR HPV, a likely
morerealisticestimate(57.2%ofLGILand70.0%ofHGIL)
of the percentage of these lesions that are attributable to
vaccine-related HR types is obtained. Including additional
HPV types in future vaccines (such as 56 and 90 in BC)
would further increase the percentage of cervical lesions
prevented. These data provide a baseline from which to
monitor changes in HPV prevalence that result from future
use of HPV vaccines in BC and may inform the use of HPV
testing as a ﬁrst-line screening alternative to cytology.
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